Polyester amide copolymers having free carboxylic acid pendant groups

Patent metadata

Field	Value
Publication number	US-9737638-B2
Application number	US-82083307-A
Country	US
Kind code	B2
Filing date	Jun 20, 2007
Priority date	Jun 20, 2007
Publication date	Aug 22, 2017
Grant date	Aug 22, 2017

Abstract

A poly(ester amide) polymer having free carboxylic acid pendant groups and method of making and using the same are disclosed.

First claim

What is claimed is:

1. A medical device comprising a coating, the coating comprising a poly(ester amide) (PEA) polymer comprising free carboxylic acid pendant groups,
wherein the free carboxylic acid pendant groups are from 2,2-dimethylolpropionic acid, wherein the PEA polymer is of formula:
[A] m -[B] n ;

wherein:

m and n are independently integers ranging from 1 to about 100,000.

2. The medical device of claim 1 , wherein the PEA polymer has an acid content of about 0.01% or above.

3. The medical device of claim 1 , wherein the PEA polymer has an acid content of about 0.1% or above.

4. The medical device of claim 1 , wherein the PEA polymer has an acid content of about 1% or above.

5. The medical device of claim 1 , wherein the PEA polymer has an acid content of about 5% or above.

6. The medical device of claim 1 , wherein the PEA polymer has an acid content of about 10% or above.

7. The medical device of claim 1 , further comprising a bioactive agent.

8. The medical device of claim 7 , wherein the bioactive agent is paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutase, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, dexamethasone acetate, rapamycin, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy] ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), γ-hiridun, clobetasol, mometasone, pimecrolimus, imatinib mesylate, or midostaurin.

9. The medical device of claim 8 , wherein the bioactive agent is everolimus.

10. The medical device of claim 1 which is a stent.

11. The medical device of claim 1 which is a bioabsorbable stent.

12. A method of treating or ameliorating a medical condition, comprising implanting in a human being the medical device of claim 7 , wherein the medical condition is selected from atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, urethra obstruction, tumor obstruction, diabetic vascular disease, and combinations thereof.

13. A method of treating or ameliorating a medical condition, comprising implanting in a human being the medical device of claim 8 , wherein the medical condition is selected from atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, urethra obstruction, tumor obstruction, diabetic vascular disease, and combinations thereof.

Assignees

• Pham Nam D
• Ngo Michael H
• Trollsas Mikael O
• Abbott Cardiovascular Systems Inc

Inventors

• Pham Nam D
• Ngo Michael H
• Trollsas Mikael O

Classifications

• C08L77/12

  Polyester-amides · CPC title

• A61L29/085 Primary

  Macromolecular materials · CPC title

• A61L31/10

  Macromolecular materials · CPC title

• A61L27/34

  Macromolecular materials · CPC title